After a long run of trial disappointments, AstraZeneca is celebrating a win for its immuno-oncology combination of Imfinzi plus tremelimumab in advanced liver cancer. The mid-stage Study 22 trial ...

UK-based pharmaceutical company AstraZeneca has reported positive results from the Phase III NIAGARA trial of Imfinzi alongside neoadjuvant chemotherapy. The combination therapy was found to ...

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in early-stage stomach cancer met its main goal. When added to a ...

Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric and gastroesophageal junction cancers. Among patients with resectable ...

The price you pay for Imfinzi may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...

Imfinzi plus chemotherapy significantly improved event-free survival in resectable Stage II-IVA gastric and GEJ cancer patients. A strong trend in overall survival benefit was observed, with final ...

AstraZeneca (AZ) has shared positive results from a late-stage trial of its Imfinzi (durvalumab)-based perioperative regimen in gastric cancer. The phase 3 MATTERHORN study has been evaluating Imfinzi ...

(RTTNews) - The Imfinzi-based regimen demonstrated a statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal ...

The Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for adults with limited-stage small cell lung cancer (SCLC) whose disease did not progress after concurrent platinum-based ...

Recommendation based on AEGEAN Phase III trial results which showed Imfinzi reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone AstraZeneca’s Imfinzi ...

WILMINGTON, Del. - AstraZeneca (AZN), a prominent player in the pharmaceuticals industry with a market capitalization of $239.77 billion, announced its IMFINZI (durvalumab) treatment has shown a ...

Also Read: AstraZeneca’s Imfinzi Perioperative Regimen Shows Improved Survival Outcomes In Bladder Cancer Patients Patients were treated with neoadjuvant Imfinzi in combination with chemotherapy ...